Nootropic Peptide Research Compound · Limited Human Data Oral / Transdermal Active

Dihexa

PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · Angiotensin IV Derivative

"The most potent synaptogenic compound ever identified — reportedly 7 million times more potent than BDNF at promoting new synapse formation. Derived from angiotensin IV. Half-life of 13 days. Oral or transdermal active. No human trials. The most extreme nootropic claim in peptide science, with animal data that demands serious investigation but extraordinary caution."

Origin
Angiotensin IV derivative · Washington State University
Claimed potency
7 million × more potent than BDNF at synaptogenesis
Half-life
~13 days · unusually long for a peptide
Routes
Oral · transdermal · SubQ
Human trials
None conducted
Origin & The Claim

The 7-million-times-BDNF nootropic

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University by Joseph Harding and Barbara McDaniel, primarily studying the role of angiotensin IV and its receptor AT4 (now identified as HGF receptor, c-MET) in cognitive function. Dihexa is a superagonist at HGF receptors — a derivative of angiotensin IV engineered for improved stability and blood-brain barrier penetration.

The claim that launched it into nootropic consciousness: in the Morris water maze (spatial memory test), Dihexa produced cognitive improvements at concentrations approximately 7 million times lower than BDNF (Brain-Derived Neurotrophic Factor) was required to produce equivalent synaptogenic effects. The mechanism: HGF/c-MET signalling promotes dendritic arborisation, synaptogenesis, and neurotrophic support through mechanisms that converge on BDNF-like downstream effects but operate through a different receptor pathway.

Two additional properties make Dihexa unusual: (1) it is orally bioavailable and crosses the blood-brain barrier — most peptides fail both tests; (2) it has a half-life of approximately 13 days — extraordinarily long for a peptide, likely due to its lipophilic hexanoic acid modification. These pharmacokinetic properties make it uniquely practical as a peptide nootropic, if the efficacy translates to humans.

Important caveat on the "7 million times" claim: This comparison is between in vitro assay conditions — the concentration of Dihexa required to produce a measurable synaptogenic effect vs BDNF. It does not mean Dihexa is 7 million times more effective as a cognitive enhancer. BDNF does not easily cross the blood-brain barrier and has poor pharmacokinetics; Dihexa's comparison advantage includes these factors. The headline number captures attention but should not be taken as a direct measure of clinical potency.

Mechanism

HGF receptor agonism — synaptogenesis from a new angle

How Dihexa Works

1
HGF receptor (c-MET) superagonism: Dihexa acts as a superagonist at c-MET (the hepatocyte growth factor receptor), which is expressed throughout the brain. HGF/c-MET signalling promotes neurite outgrowth, dendritic branching, and synapse formation through the PI3K/Akt and MAPK/ERK pathways — the same downstream signals that BDNF activates through TrkB, but accessed through a completely different receptor.
2
Blood-brain barrier penetration: Most peptides fail to penetrate the blood-brain barrier due to their hydrophilicity and molecular weight. Dihexa's lipophilic hexanoic acid modification and small size enable passive BBB diffusion — the same challenge that prevents BDNF itself from being a practical therapeutic despite its well-established neuroprotective effects.
3
Synaptogenesis — structural changes: In animal models, Dihexa administration produced measurable increases in dendritic spine density and synapse number in hippocampal neurons. These are structural changes to neural architecture — not just functional modulation — which may explain why some community users report effects that persist well after dosing stops.
4
Alzheimer's models: In scopolamine-induced amnesia models and aged rat cognitive decline models, Dihexa significantly reversed learning and memory deficits. These are the animal models most relevant to neurodegenerative disease rather than healthy cognitive enhancement.

The 13-day half-life is a double-edged characteristic. It enables infrequent dosing (some users report dosing once per week or less). But it also means that if adverse effects occur, they cannot be rapidly reversed by stopping the compound. The accumulation over time with repeated dosing must be considered. Community protocols typically use conservative doses with long intervals precisely because of this pharmacokinetic profile.

Community Voices

What people report

Anecdotal ReportNot medical evidence · Research compound use

"Used Dihexa transdermally at 2mg twice weekly for 6 weeks. The cognitive effect was different from other nootropics — more like improved pattern recognition and faster retrieval rather than stimulant-like alertness. Effects seemed to persist even weeks after stopping. The 13-day half-life makes it genuinely cumulative."

Male, 47. The persistence of effects after stopping is consistently reported and mechanistically consistent with the structural synaptogenesis hypothesis — new synapses don't disappear immediately when the peptide clears. Whether this represents genuine neuroplasticity or some other mechanism in humans is unknown.

Anecdotal Report — NegativeNot medical evidence · Research compound use

"I used too much too soon — 10mg dose. Experienced significant anxiety and irritability for 2 weeks that I couldn't switch off. The long half-life meant I had no way to accelerate clearance. Important lesson: start extremely low with this compound."

Female, 33. This report illustrates the critical risk with long half-life compounds — if something goes wrong, you wait it out. Community consensus is extremely conservative dosing: 1–3mg, infrequent dosing, extended observation periods between doses.

Safety — The Long Half-life Problem

Risks & the irreversibility concern

🚨
No human safety trials. 13-day half-life means adverse effects cannot be rapidly reversed. This combination requires exceptional caution. Unlike peptides that clear in hours, any adverse reaction to Dihexa persists for weeks. The c-MET receptor has roles in cell proliferation across multiple tissues — systemic c-MET superagonism at high doses could theoretically promote tumour growth. No long-term safety data exists.
Serious
Irreversible effects from long half-life — 13 days means any side effect (anxiety, irritability, cognitive effects, or unknown systemic effects) will persist for 2–4 weeks minimum before the compound clears. There is no antidote. Start extremely low and observe for extended periods.
Unknown
c-MET activation and cancer risk — c-MET is a proto-oncogene. HGF/c-MET signalling is involved in tumour growth and metastasis. Whether Dihexa's c-MET agonism at neurotrophic doses poses cancer risk is completely unknown. Contraindicated in anyone with active or recent malignancy.
Unknown
Cumulative accumulation — repeated dosing accumulates the compound. The relationship between cumulative dose and effect/toxicity has not been characterised in humans.
Moderate
Anxiety and irritability — reported at higher doses. May relate to excessive HGF signalling or indirect effects on monoamine systems. Dose-dependent and resolves after clearance — but clearance takes weeks.
Honest Assessment

Editor's summary

Dihexa is the most pharmacologically interesting nootropic compound in this book — and the one that demands the most caution. The mechanism is genuinely novel (HGF/c-MET synaptogenesis), the oral bioavailability and BBB penetration are rare for peptides, and the animal cognitive data is compelling for neurodegenerative disease contexts. The 7 million times BDNF claim, while headline-grabbing, reflects assay conditions rather than clinical reality.

The absence of human safety data combined with a 13-day half-life is a serious barrier. The c-MET proto-oncogene concern is not paranoia — it is basic pharmacology that must be acknowledged. Dihexa should not be used by anyone with a cancer history, anyone who can't tolerate weeks of potential side effects, or anyone who hasn't done extensive research into the available animal literature. If you use it at all: start at the lowest plausible dose, dose infrequently, and observe carefully for extended periods before escalating.

Verdict
"The most extreme nootropic claim in peptide science — 7 million times BDNF potency at synaptogenesis. Genuinely novel mechanism. No human safety data. A 13-day half-life that makes adverse effects hard to reverse. The c-MET proto-oncogene concern is real. Start extremely low or wait for human safety data."